Acadia Pharmaceuticals
| Use attributes for filter ! | |
| Web site | www.acadia-pharm.com |
|---|---|
| Headquarters | San Diego |
| California | |
| United States | |
| Revenue | 223. 8 million USD (2018) |
| Number of employees | 400 |
| Founded | 1993 |
| Stock price | ACAD |
| Disclaimer | |
| Subsidiaries | ACADIA Pharmaceuticals A/S |
| ACADIA Pharmaceuticals AB | |
| ACADIA Pharmaceuticals GmbH | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 672625 |
About Acadia Pharmaceuticals
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in San Diego, California. On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
